Chase ML et al. Consensus recommendations on peripheral blood smear review: Defining curricular standards and fellow competency. Blood Adv 2023;7(13):3244-52. Abstract
Chase ML et al. Development of consensus guidelines for hematology fellow competency in peripheral blood smear review utilizing nominal group technique 3204. Blood 2022;140(Supplement 1):10781-3. Abstract
Duminuco A et al. ACVR1: A novel therapeutic target to treat anemia in myelofibrosis. Cancers 2024;16(1):154. Abstract
Gangat N et al. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol 2023;98(2):282-9. Abstract
Gerds AT et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): An updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol 2023;10(9):e735-46. Abstract
Gerds AT et al. Ruxolitinib for myelofibrosis in elderly non-transplant patients: Healthcare resource utilization and costs. J Med Econ 2023;26(1):843-9. Abstract
Gupta V et al. Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial. ASCO 2024;Abstract 6571.
Harrison CN et al. Clinical effectiveness and safety of momelotinib compared with continued ruxolitinib or best available therapy in patients with myelofibrosis who required RBC transfusions: Subgroup analysis of the phase 3 Simplify-2 study. ASH 2023;Abstract 2189.
Kong T et al. Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms. Am J Hematol 2023;98(7):1029-42. Abstract
Kremyanskaya M et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med 2024;390(8):723-35. Abstract
Kuzmanovic T et al. Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience. ASCO 2023;Abstract 7010.
Mendez LF et al. Mediterranean diet intervention in patients with myeloproliferative neoplasm. Blood 2022;140(Suppl 1):3972-3. Abstract
Mesa R et al. Clinical outcomes of patients with myelofibrosis after immediate transition to momelotinib from ruxolitinib. Haematologica 2024;109(2):676-81. Abstract
Mishra R et al. Risk of myelodysplastic syndromes (MDS) in adolescents and young adults with cancers treated with chemotherapy with or without radiotherapy. ASH 2023;Abstract 2351.
Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. Blood Adv 2023;7(19):5835-42. Abstract
Pemmaraju N et al. Ten years after ruxolitinib approval for myelofibrosis: A review of clinical efficacy. Leuk Lymphoma 2023;64(6):1063-81. Abstract
Pemmaraju N et al. TRANSFORM-1: A randomized, double-blind, placebo-controlled, multicenter, international phase 3 study of navitoclax in combination with ruxolitinib versus ruxolitinib plus placebo in patients with untreated myelofibrosis. ASH 2023;Abstract 620.
Rampal RK et al. Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-naïve patients with myelofibrosis: Results of the MANIFEST-2 randomized, double-blind, phase 3 study. ASH 2023;Abstract 628.
Scandura JM et al. Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis and moderate thrombocytopenia. ASCO 2024;Abstract TPS6593.
Scandura JM et al. A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in patients with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia (XPORT-MF-044). ASH 2023;Abstract 3211.
Tantravahi SK et al. Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naïve patients with myelofibrosis: Long-term follow-up from XPORT-MF-034 suggestive of disease modification. ASH 2023;Abstract 622.
Verstovsek S et al. Momelotinib long-term safety and survival in MF: Integrated analysis of phase III randomized controlled trials. Blood Adv 2023;7(14):3582-91. Abstract
Verstovsek S et al. Momelotinib versus danazol in symptomatic patients with anaemia and MF (MOMENTUM): Results from an international, double-blind, randomised, controlled, phase III study. Lancet 2023;401(10373):269-80. Abstract